Evonik’s “Market Impact” award-winning EUDRAGIT® functional film coating polymers are widely recognized as an industry standard for oral controlled drug delivery. Used in more than 80 countries and cited in over 23,000 patents, EUDRAGIT® was introduced to China in the 1990s. Since then, it has played a pivotal role in advancing solid oral dosage form technologies. Its broad adoption in locally developed controlled- and sustained-release formulations has contributed to improved product quality and supported Chinese pharmaceutical companies in their transition from high-quality generics to innovative, proprietary drug delivery solutions.
Recognized in the “Advanced Technology” category, EUDRACAP® colon is the first ready-to-fill functional capsule on the market to target the ileo-colonic region. It enables the safe and effective oral delivery of sensitive active pharmaceutical ingredients (APIs) while helping to accelerate drug development timelines. The capsules are compatible with powders, pellets, and granules, and can be easily processed using standard capsule filling equipment.
The Pharma Excipients Awards, a flagship category of the CPHI China Celebration Awards, honor breakthrough excipient technologies and high-potential products that elevate industry standards and promote high-quality pharmaceutical development. EUDRACAP® colon also gained international acclaim at the CPHI Pharma Awards in Frankfurt in 2025.
Evonik Health Care has been a leader in advanced drug delivery for decades, supporting pharmaceutical companies worldwide with comprehensive services for the development of complex oral and parenteral drug products. This includes pharmaceutical excipients, formulation development and the manufacture of clinical samples, as well as commercial drug products. Furthermore, the business serves as a CDMO for APIs and intermediates and has a strong focus on growth fields such as lipid-based mRNA and gene delivery, and cell culture solutions for biopharma applications.
